I see the guy from Amgen(AMGN) will be with her as well.
Meanwhile, Roche (Genentech; California) has reached phase 3 development with its PD-L1 inhibitor, MPDL3280A; AstraZeneca and its global biologics R&D arm MedImmune (Maryland) are also in phase 3 development with their PD-L1 inhibitor MEDI4736, and earlier clinical development with their PD-1 inhibitor MEDI0680 (AMP-514); and Merck Serono, the biopharmaceutical division of Merck KGaA (Darmstadt, Germany), is conducting a phase 2 trial with its PD-L1 inhibitor MSB0010718C.
NewLink Genetics Corporation has announced the beginning of an exclusive license agreement with Genentech for the development of NLG919, an IDO pathway inhibitor. Furthermore, both companies will also collaborate in the research for next generation IDO/TDO compounds. Belonging to the growing class of checkpoint inhibitors, such as...
NEW YORK (TheStreet) -- "Immuno-oncology" will be the dominant buzz phrase at this year's American Society of Clinical Oncology (ASCO) annual meeting, just like last year. New classes of drugs designed to dismantle cloaking mechanisms used by cancer cells to hide from a patient's immune system are generating a tremendous amount of excitement in the cancer research community.
Investors are fixated on immuno-oncology drugs, too, with most of the attention being paid to the anti-PD1 and anti-PDL-1 "checkpoint inhibitors" under development by Bristol-Myers Squibb (BMY), Merck (MRK) and Roche (RHHBY). This year marks the ASCO "debut" of AstraZeneca (AZN) to the checkpoint inhibitor race.
UCLA video proves NWBO success. MD Anderson and FDA working closely with NWBO in all cancers.
UCLA proves NWBO drug is best of breed. MD Anderson working with all cancers with NWBO.
UCLA proves NWBO drug is best of breed in Immunotherapy. Used in all cancers at MD Anderson. Watch video.
NWBO best of breed in immunotherapy. Watch video from UCLA oncologists.
NWBO drugs are best of breed..Watch video.
On its inevitable move to triple digits.
Anyone who is not a dope already knew Linda says separate negotiations from each department and each hospital takes time.
Dude you better do your homework or u will be left in the dust. See Linda Powers latest presentation. its like 44 minutes long. Not summarizing for you.